Literature DB >> 3485071

Treatment of bacterial vaginosis with an acid cream: a comparison between the effect of lactate-gel and metronidazole.

B Andersch, L Forssman, K Lincoln, P Torstensson.   

Abstract

Bacteriological isolation of anaerobes, Gardnerella and lactobacilli was carried out in a group of 62 women with the diagnosis bacterial vaginosis and 42 control women. Lactobacilli were the predominant organisms in the control group whereas anaerobes dominated the flora in bacterial vaginosis patients. Lactate-gel (pH 3.5, 5 ml) inserted into the vagina daily for 7 days is as effective as oral metronidazole, 500 mg twice daily for 7 days. The women in both groups became symptom-free and objectively improved. Anaerobes were significantly reduced (p less than 0.0001) in both groups after 1-week treatment but Gardnerella was not significantly reduced. As bacterial vaginosis is generally looked upon as a mild noninflammatory condition lactate-gel seems to be an ideal treatment for this disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485071     DOI: 10.1159/000298923

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  11 in total

1.  A pilot clinical trial comparing an acid-buffering formulation (ACIDFORM gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis.

Authors:  Jose A Simoes; Luis G Bahamondes; Rodrigo P S Camargo; Valeria M N Alves; Lourens J D Zaneveld; Donald P Waller; Jill Schwartz; Marianne M Callahan; Christine K Mauck
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

Review 2.  Bacterial vaginosis.

Authors:  C A Spiegel
Journal:  Clin Microbiol Rev       Date:  1991-10       Impact factor: 26.132

3.  Non-antibiotic treatment of bacterial vaginosis-a systematic review.

Authors:  Fiona Damaris Tidbury; Anita Langhart; Susanna Weidlinger; Petra Stute
Journal:  Arch Gynecol Obstet       Date:  2020-10-06       Impact factor: 2.344

4.  Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification.

Authors:  E R Boskey; K M Telsch; K J Whaley; T R Moench; R A Cone
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

5.  Zinc Lactate and Sapindin Act Synergistically with Lactocin 160 Against Gardnerella vaginalis.

Authors:  Yevgeniy Turovskiy; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2011-06-01       Impact factor: 4.609

6.  Vaginal treatment with lactic acid gel delays relapses in recurrent urinary tract infections: results from an open, multicentre observational study.

Authors:  Ruth Diebold; Bettina Schopf; Holger Stammer; Werner Mendling
Journal:  Arch Gynecol Obstet       Date:  2021-03-27       Impact factor: 2.344

Review 7.  Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health.

Authors:  Mariya I Petrova; Elke Lievens; Shweta Malik; Nicole Imholz; Sarah Lebeer
Journal:  Front Physiol       Date:  2015-03-25       Impact factor: 4.566

8.  Vaginal concentrations of lactic acid potently inactivate HIV.

Authors:  Muriel Aldunate; David Tyssen; Adam Johnson; Tasnim Zakir; Secondo Sonza; Thomas Moench; Richard Cone; Gilda Tachedjian
Journal:  J Antimicrob Chemother       Date:  2013-05-08       Impact factor: 5.790

Review 9.  Interplay Between the Host, the Human Microbiome, and Drug Metabolism.

Authors:  Robert G Nichols; Jeffrey M Peters; Andrew D Patterson
Journal:  Hum Genomics       Date:  2019-06-11       Impact factor: 4.639

10.  Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis.

Authors:  Lindsay Armstrong-Buisseret; Clare Brittain; Miruna David; Gillian Dean; Frances Griffiths; Trish Hepburn; Louise Jackson; Joe Kai; Alan Montgomery; Tracy Roberts; Sukhwinder Thandi; Jonathan D C Ross
Journal:  Trials       Date:  2019-11-27       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.